BLUEBIRD BIO INC stock forecast: down to 1.45 USD BLUE stock price prognosis


Forecast for Fri 19 Apr 2024 price 1.45

BLUEBIRD BIO INC stock price forecast for further price development down to -49.71% (time horizon: 1 day) and price target of 1.45 USD. Short-term (time horizon: 2 weeks) BLUEBIRD BIO INC share price prediction for 2024-04-19 with daily closed price projections

Key Facts

Symbol BLUE 

ISIN US09609G1004 

CUSIP 09609G100

Currency USD

Category Biological Products (No Diagnostic Substances)

Forecast price change %

Relative Strength Index (RSI)

Finance numbers

Revenue 241,665,000.0

Earnings per share -9.38

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

In addition, the EMA has granted Priority Medicines (PRIME) eligibility for beti-cel. Approximately fifty adult and adolescent patients are enrolled in the study. Eli-cel has been granted Orphan Drug status by the FDA and EMA for adrenoleukodystrophy. Patients will be followed for 24 months post-treatment under this protocol. Target enrollment in ALD-104 is 35 patients. Cytopenias were common and not dose related. Sixty-nine patients received treatment as of the data cut-off. However, trade secrets can be difficult to protect. We have the right to grant sublicenses outright to third parties under the agreement. We must report on our progress towards achieving these milestones on an annual basis. Absent early termination, the license will expire in April 2037. This percentage varies from mid-single digits to low double digits. We may unilaterally terminate the license agreement upon six months' notice to MIT. For each such sublicense we grant we must pay the NIH a fee. Orphan product designation must be requested before submitting an NDA or BLA. As a result, increasingly high barriers are being erected to the entry of new products. We also have several programs in late-stage clinical development. We rely on a complex supply chain for ZYNTEGLO and our product candidates. Reimbursement agencies in Europe may be more conservative than CMS. There is a high failure rate for drugs and biologics proceeding through clinical studies. As of December 31, 2020, we had 1,201 full-time employees. Competition for skilled personnel is intense and the turnover rate can be high. These reductions were extended through 2029 through subsequent legislative amendments. Such a loss of patent protection would have a material adverse impact on our business. Changes in tax law could adversely affect our business and financial condition.

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 47.74/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.
    • Stock price is under book price value.

Institutional ownership list is based on filling form information

Holding name Date Amount
A - BARCLAYS PLC 2023-06-30 750753
A - OVERSEA-CHINESE BANKING Corp Ltd 2022-12-31 24451
China Universal Asset Management Co., Ltd. 2023-06-30 1395
MetLife Investment Management, LLC 2022-12-31 43619

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Pacer Funds Trust 2023-07-31 12384 Long
Columbia Funds Series Trust I 2023-11-30 267400 Long
ProShares Trust 2023-11-30 6798 Long
ProShares Trust 2023-11-30 8620 Long

Insider trading for BLUEBIRD BIO INC

CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1629278 Klima Thomas J 2023-09-05 SALE Accept Accept Accept Accept
1839697 Obenshain Andrew 2023-11-03 SALE Reject Reject Reject Accept
1944069 Colvin Richard A 2023-11-02 SALE Accept Accept Accept Accept

Bollinger Bollinger Bands for BLUEBIRD BIO INC can provide the information where the market is moving based on price information.

BLUEBIRD BIO INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

Converting prices to returns BLUEBIRD BIO INC.

On-Balance Volume information for BLUEBIRD BIO INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for BLUEBIRD BIO INC. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for BLUEBIRD BIO INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for BLUEBIRD BIO INC. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for BLUEBIRD BIO INC. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for BLUEBIRD BIO INC. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for BLUEBIRD BIO INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

Heikin Ashi trading signals are generated based on the Heikin Ashi candles, which are a type of candlestick that smooths out the price action and can help to identify trends. Heikin Ashi signals can be used to identify both long and short trading opportunities.

The awesome oscillator is a momentum indicator that measures the speed and strength of price movements. It is calculated by subtracting a 34-period simple moving average (SMA) from a 5-period SMA.

The Parabolic SAR indicator is a trend-following indicator that uses a series of dots to indicate when a trend is likely to reverse. The Parabolic SAR is a lagging indicator, meaning that it does not predict reversals, but rather confirms them after they have already occurred.

Moving Average Crossover

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2024-04-19 1.45 2024-02-24 12:56
2024-03-25 1.35 2024-02-24 12:56
2024-03-26 1.35 2024-02-24 12:56
2024-04-02 1.38 2024-02-24 12:56
2024-04-03 1.38 2024-02-24 12:56
2024-04-04 1.39 2024-02-24 12:56
2024-03-21 1.33 2024-02-24 12:56
2024-03-11 1.28 2024-02-24 12:56
2024-03-22 1.34 2024-02-24 12:56
2024-03-27 1.36 2024-02-24 12:56
2024-03-28 1.36 2024-02-24 12:56
2024-03-29 1.37 2024-02-24 12:56
2024-03-15 1.31 2024-02-24 12:56
2024-04-18 1.44 2024-02-24 12:56
2024-03-13 1.30 2024-02-24 12:56
2024-02-27 1.26 2024-02-24 12:56
2024-02-28 1.28 2024-02-24 12:56
2024-02-29 1.27 2024-02-24 12:56
2024-03-01 1.25 2024-02-24 12:56
2024-03-14 1.30 2024-02-24 12:56
2024-03-18 1.31 2024-02-24 12:56
2024-03-19 1.32 2024-02-24 12:56
2024-03-08 1.27 2024-02-24 12:56
2024-03-12 1.30 2024-02-24 12:56
2024-03-20 1.33 2024-02-24 12:56
2024-04-01 1.37 2024-02-24 12:56
2024-04-08 1.40 2024-02-24 12:56
2024-04-09 1.41 2024-02-24 12:56
2024-03-04 1.26 2024-02-24 12:56
2024-03-05 1.24 2024-02-24 12:56
2024-03-06 1.26 2024-02-24 12:56
2024-03-07 1.26 2024-02-24 12:56
2024-04-15 1.43 2024-02-24 12:56
2024-04-16 1.43 2024-02-24 12:56
2024-04-17 1.44 2024-02-24 12:56
2024-04-05 1.40 2024-02-24 12:56
2024-04-10 1.41 2024-02-24 12:56
2024-04-12 1.42 2024-02-24 12:56
2024-04-11 1.42 2024-02-24 12:56

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.